Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Receivables - Net: 2009-2025

Historic Receivables - Net for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to $252.6 million.

  • Ani Pharmaceuticals' Receivables - Net rose 28.65% to $252.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $252.6 million, marking a year-over-year increase of 28.65%. This contributed to the annual value of $221.7 million for FY2024, which is 36.80% up from last year.
  • Ani Pharmaceuticals' Receivables - Net amounted to $252.6 million in Q3 2025, which was up 11.95% from $225.7 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Receivables - Net's 5-year high stood at $252.6 million during Q3 2025, with a 5-year trough of $91.9 million in Q1 2021.
  • For the 3-year period, Ani Pharmaceuticals' Receivables - Net averaged around $194.9 million, with its median value being $178.8 million (2023).
  • As far as peak fluctuations go, Ani Pharmaceuticals' Receivables - Net soared by 62.35% in 2022, and later dropped by 3.95% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Receivables - Net (Quarterly) stood at $128.5 million in 2021, then increased by 28.72% to $165.4 million in 2022, then fell by 2.03% to $162.1 million in 2023, then surged by 36.80% to $221.7 million in 2024, then increased by 28.65% to $252.6 million in 2025.
  • Its last three reported values are $252.6 million in Q3 2025, $225.7 million for Q2 2025, and $220.3 million during Q1 2025.